The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment
- PMID: 36415058
- DOI: 10.1002/jmv.28330
The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical